- Home
- VMCAU vs INSM Comparison
VMCAU vs INSM Comparison
Compare VMCAU & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMCAU
- INSM
- Stock Information
- Founded
- VMCAU N/A
- INSM 1988
- Country
- VMCAU
- INSM United States
- Employees
- VMCAU N/A
- INSM N/A
- Industry
- VMCAU
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- VMCAU
- INSM Health Care
- Exchange
- VMCAU NYSE
- INSM Nasdaq
- Market Cap
- VMCAU N/A
- INSM 13.7B
- IPO Year
- VMCAU N/A
- INSM 2000
- Fundamental
- Price
- VMCAU $11.51
- INSM $81.20
- Analyst Decision
- VMCAU
- INSM Strong Buy
- Analyst Count
- VMCAU 0
- INSM 16
- Target Price
- VMCAU N/A
- INSM $84.29
- AVG Volume (30 Days)
- VMCAU N/A
- INSM 2.0M
- Earning Date
- VMCAU N/A
- INSM 02-20-2025
- Dividend Yield
- VMCAU N/A
- INSM N/A
- EPS Growth
- VMCAU N/A
- INSM N/A
- EPS
- VMCAU N/A
- INSM N/A
- Revenue
- VMCAU N/A
- INSM $342,958,000.00
- Revenue This Year
- VMCAU N/A
- INSM $19.74
- Revenue Next Year
- VMCAU N/A
- INSM $43.16
- P/E Ratio
- VMCAU N/A
- INSM N/A
- Revenue Growth
- VMCAU N/A
- INSM 22.13
- 52 Week Low
- VMCAU N/A
- INSM $21.92
- 52 Week High
- VMCAU N/A
- INSM $81.25
- Technical
- Relative Strength Index (RSI)
- VMCAU 53.89
- INSM 69.09
- Support Level
- VMCAU $11.52
- INSM $74.47
- Resistance Level
- VMCAU $11.69
- INSM $80.63
- Average True Range (ATR)
- VMCAU 0.01
- INSM 2.88
- MACD
- VMCAU 0.01
- INSM 0.59
- Stochastic Oscillator
- VMCAU 28.00
- INSM 94.15
About VMCAU VALUENCE MERGER CORP
Valuence Merger Corp I is a blank check company.
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.